Table 2 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• Significant efficacy was demonstrated in the treatment of metastatic solid tumors with zilovertamab vedotin.
• Efficacy results show a promising response rate among participants treated with zilovertamab vedotin.
• Analysis was conducted in the framework of a phase 2 study assessing zilovertamab vedotin's effectiveness.
• Findings highlight the need for further exploration of zilovertamab vedotin in diverse tumor types.